|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Type II-Open (Type II-O) pit pattern is highly specific to sessile serrated adenoma/polyps (SSA/Ps), and Type-II-O-positive tumors frequently exhibit v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation and 5'-C-phosphate-G-3' (CpG) island hypermethylation.
|
30554192 |
2019 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The sessile serrated adenoma/polyp (SSA/P) has been proposed as the precursor lesion of CRCs characterized by CpG island methylator phenotype (CIMP), DNA mismatch repair (MMR) system deficiency, and BRAF gene mutations.
|
30738693 |
2019 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Type II-O was tightly associated with sessile serrated adenoma/polyps (SSA/Ps) with BRAF mutation and CIMP-high.
|
29546645 |
2018 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Active BRAF-V600E is the key player in generation of a sessile serrated polyp-specific DNA methylation profile.
|
29590112 |
2018 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyp (SSA/P) is regarded as a genetically homogeneous entity, with most lesions harbouring the BRAF V600E mutation.
|
29920740 |
2018 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyps (SSA/Ps), which are precursor lesions of colorectal cancer (CRC) with BRAF mutation and the CpG island methylator phenotype (CIMP), develop cytologic dysplasia (CD) during the progression of colorectal tumorigenesis.
|
28501592 |
2017 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The unique molecular spectrum of these tumors suggests a stepwise neoplastic progression from sessile serrated adenoma to traditional serrated adenoma and BRAF-mutated/microsatellite-stable colorectal carcinoma, which should be recognized as the traditional serrated pathway to distinguish from the sessile serrated pathway.
|
27305845 |
2016 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A series of 330 colorectal polyps including 218 serrated polyps [42 goblet cell-rich hyperplastic polyps (GCHP), 68 microvesicular hyperplastic polyps (MVHP), 100 sessile serrated adenoma (SSA) and eight traditional serrated adenoma (TSA)] and 112 conventional adenomas was analyzed for BRAF/KRAS mutations, MSI, CIMP, MLH1 and MGMT methylation, and MUC2 and MUC5AC expression and methylation.
|
26476272 |
2016 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P.
|
25314065 |
2015 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V600E mutation may be the key to identify lesions with higher potential to progression into sessile serrated adenoma/polyp, and further to BRAF V600E-mutated colorectal cancer.
|
23887306 |
2014 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that SSA-associated synchronous colorectal carcinomas have a striking predilection for elderly women, are associated with a favorable prognosis, and are MSI-H and BRAF V600E positive.
|
23887157 |
2013 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Precursor polyps include sessile serrated adenoma (SSA), characterized by proximal location, crypt architectural disturbance, and BRAF mutation.
|
23339363 |
2013 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations (V600E) were observed in 45.8% (11 of 24) of HPs, 60.9% (14 of 23) of SSAs, and 63.6% (7 of 11) of SSANs, and were equally found in both SSA and carcinoma/HGD areas of the individual SSANs.
|
21263251 |
2011 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation analysis was performed in 148 selected cases; mutations were found in 44/49 (90%) of lesions diagnosed as sessile serrated adenoma, in 10/34 (29%) of hyperplastic polyps of microvesicular type, in 4/11 (36%) of traditional serrated adenomas, in 10/10 (100%) of mixed hyperplastic adenomatous polyps, and in 2/42 (5%) of "conventional" adenomas.
|
19126563 |
2009 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A BRAF mutation was present in 82% of serrated carcinomas (SCas), 62% of serrated adenomas (SAs), 83% of serrated polyps with abnormal proliferation (SPAPs-syn. sessile serrated adenoma [SSA]), 76% of microvesicular serrated polyps (MVSPs), and was not found in any of the histologic categories of the traditional adenoma-carcinoma sequence.
|
17122504 |
2006 |